Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Vaxcyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Vaxcyte şirketinin toplam hissedar öz sermayesi $2.0B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $2.1B ve $101.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.45b
Eşitlik	US$1.99b
Toplam yükümlülükler	US$101.14m
Toplam varlıklar	US$2.09b

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Dec 22

Recent updates

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 06

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Aug 24

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

May 10

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Dec 27

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Sep 12

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

May 30

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Dec 22

Vaxcyte appoints new CBO, CMO

Oct 11

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Aug 05

Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate

Jul 12

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Feb 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PCVX 'nin kısa vadeli varlıkları ( $1.5B ) kısa vadeli yükümlülüklerini ( $82.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: PCVX şirketinin kısa vadeli varlıkları ( $1.5B ) uzun vadeli yükümlülüklerini ( $18.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PCVX borçsuzdur.

Borcun Azaltılması: PCVX şirketinin 5 yıl önce borç/öz sermaye oranı 2.6% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PCVX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: PCVX serbest nakit akışı her yıl % 50.3 2.8 yıl yetecek nakit akışına sahip olacaktır.

Vaxcyte Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Recent updates

Co-Founder notifies of intention to sell stock

Executive VP & COO notifies of intention to sell stock

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

Executive VP & COO notifies of intention to sell stock

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Price target increased by 27% to US$131

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate

President & CFO notifies of intention to sell stock

President & CFO notifies of intention to sell stock

Vaxcyte Appoints John Furey to Board of Directors

President & CFO notifies of intention to sell stock

Independent Director notifies of intention to sell stock

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry?

President & CFO notifies of intention to sell stock

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

President & CFO notifies of intention to sell stock

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

New major risk - Revenue and earnings growth

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Price target increased by 7.8% to US$71.14

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Co-Founder notifies of intention to sell stock

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Senior VP notifies of intention to sell stock

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

President & CFO notifies of intention to sell stock

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

President & CFO notifies of intention to sell stock

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Co-Founder notifies of intention to sell stock

We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

President exercised options to buy US$1.1m worth of stock.

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Executive VP & COO exercised options to buy US$5.1m worth of stock.

We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

Independent Director exercised options and sold US$131k worth of stock

High number of new directors

Price target increased to US$60.50

Independent Director exercised options and sold US$147k worth of stock

Price target increased to US$56.00

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte appoints new CBO, CMO

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Co-Founder notifies of intention to sell stock

Co-Founder & VP of Research notifies of intention to sell stock

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock